EtamsylateThird Party Manufacturing in India

Etamsylate works by enhancing capillary wall resistance and improving platelet adhesion, making it an effective haemostatic agent. It reduces capillary exudation and blood loss by stabilizing the endothelial lining of small blood vessels. The drug increases platelet adhesiveness at sites of vascular injury, promoting the formation of a robust platelet plug during the initial phase of haemostasis. Etamsylate also inhibits prostaglandin synthesis, particularly prostacyclin, a potent vasodilator and platelet disaggregation promoter. By reducing prostacyclin levels, Etamsylate creates a favourable environment for platelet aggregation and vasoconstriction at injury sites. This dual mechanism — capillary stabilization and platelet function enhancement — distinguishes it from other haemostatic agents like tranexamic acid, which works through antifibrinolytic pathways. Etamsylate is rapidly absorbed orally, reaching peak plasma concentrations within 4 to 5 hours, and is extensively metabolized in the liver before renal excretion. Its favourable safety profile and quick onset of action make it suitable for both prophylactic and therapeutic use in bleeding disorders across a wide patient population.

Therapeutic Uses

Etamsylate is prescribed for the prevention and treatment of capillary haemorrhages associated with a variety of clinical conditions:

• Menorrhagia: Etamsylate is widely used for managing excessive menstrual bleeding, reducing blood loss and improving quality of life in women with heavy periods.
• Surgical Bleeding Prophylaxis: It is administered before and after surgical procedures — including dental, ophthalmic, ENT, and gynaecological surgeries — to reduce intraoperative and postoperative blood loss.
• Neonatal Intraventricular Haemorrhage: Etamsylate has been studied for preventing periventricular haemorrhage in preterm neonates, though evidence remains mixed.
• Haematuria, Epistaxis, and Haemoptysis: It is used to control bleeding from the urinary tract, nasal passages, and respiratory tract.
• Postpartum Haemorrhage: The drug is employed to control excessive bleeding following childbirth.

Why Manufacturers Choose Etamsylate

Etamsylate is a high-demand molecule in the Indian pharmaceutical manufacturing market due to its established safety profile, multiple dosage forms, and consistent prescription volume across gynaecology, surgery, and paediatrics. It is available as 250 mg and 500 mg tablets, making it versatile for different patient populations. Indian manufacturers benefit from its inclusion in WHO-GMP production lines and its export potential to regulated markets including the UK, Middle East, and Africa. The molecule has a well-documented API synthesis route and stable supply chain for raw materials, making it commercially attractive for third-party manufacturing and PCD franchise operations.

This makes Etamsylate one of the most sought-after haemostatic agents for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented pharmaceutical companies.